BioSpace News Archive

Anika Therapeutics, Inc., a global joint preservation company focused on early intervention orthopedics, announced that Cingal® met its primary endpoint in a Phase III Study, demonstrating superiority over triamcinolone hexacetonide steroid alone at 26 weeks post-treatment.

Olema Pharmaceuticals, Inc. today announced that the Company will present at the following investor conferences in November.

Vyant Bio, Inc. is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Denali Therapeutics Inc. today announced interim results from Part A of a Phase 1/2 study evaluating TAK-594/DNL593 (PTV:PGRN) in healthy subjects.

DENTSPLY SIRONA Inc. announced the completion of the previously disclosed internal investigation into certain financial reporting matters.

A new study published in JAMA demonstrated that patients at high risk for acute kidney injury, the most common complication of percutaneous coronary intervention, had a significant reduction in AKI when cardiologists used Terumo Health Outcomes’ ePRISM clinical decision support platform.

Hummingbird Bioscience today announced that Chief Financial Officer Josh House and Chief Development Officer Leah DiMascio will participate in one-on-one investor meetings at the Credit Suisse 31st Annual Global Healthcare Conference on November 7 - 10, 2022 at the Terranea Resort in Rancho Palos Verdes, CA.

Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced that the first patient has been dosed in a clinical trial being conducted by Merck, known as MSD outside the United States and Canada, to evaluate a solid tumor targeting TriNKET developed by Dragonfly.

KaliVir Immunotherapeutics, Inc. announced the appointment of Adina Pelusio, M.S., as Senior Vice President of Clinical Operations.

Insmed Incorporated today announced that management will present at the following investor conferences.